- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Jennifer Caswell-Jin, MD
Postdoctoral Fellow in Medical Oncology
Conquer Cancer Foundation of ASCO
Seeking to understand why some patients have an exceptional response to chemotherapy.
Studies are conducted to compare clinical and tumor profiles in metastatic breast cancer (MBC) patients with exceptional response to other MBC patients.
This research may help answer questions about exceptional response that could lead to better outcomes for metastatic breast cancer patients.
Metastatic breast cancer remains an incurable disease. However, a subset of metastatic patients live a long time with standard therapy. What distinguishes these long-term survivors is poorly understood. It could be that the disease is exceptionally slow-growing, but it may also be that they are exceptionally sensitive to treatment.
Some metastatic breast cancer patients have excellent responses and long-term stability with a commonly used drug called capecitabine. Dr. Caswell-Jin wants to understand what is unique about these patients and their tumors. She will examine clinical characteristics and gene expression profiles of tumors from a group exceptional responders to those of other metastatic breast cancer patients.
Results fom these studies may help identify which patients are most likely to benefit from capecitabine, as well as inform strategies to improve response in more breast cancer patients.
Dr. Jennifer Caswell-Jin is a postdoctoral fellow in medical oncology at Stanford University. She attended Harvard College and Harvard Medical School and then completed her residency training in internal medicine at the University of California, San Francisco.
Her clinical practice centers around breast cancer genetics and genomics, including the care of patients carrying high-risk germline mutations and the use of targeted therapy to personalize cancer treatment. Her research is on the translational application of next-generation sequencing technologies to breast cancer care. In particular, she studies the mechanisms by which inherited genetic variants lead to breast cancer development, and analyzes somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.